A Deletion in the Gene Encoding the CD45 Antigen in a Patient with SCID

Elma Z. Tchilian, Diana L. Wallace, R. Spencer Wells, Darren R. Flower, Gareth Morgan and Peter C. L. Beverley

_J Immunol_ 2001; 166:1308-1313; doi: 10.4049/jimmunol.166.2.1308

http://www.jimmunol.org/content/166/2/1308

References  This article cites 32 articles, 12 of which you can access for free at: http://www.jimmunol.org/content/166/2/1308.full#ref-list-1

Why _The JI_? Submit online.

- Rapid Reviews! 30 days* from submission to initial decision
- No Triage! Every submission reviewed by practicing scientists
- Fast Publication! 4 weeks from acceptance to publication

*average

Subscription  Information about subscribing to _The Journal of Immunology_ is online at: http://jimmunol.org/subscription

Permissions  Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts  Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
A Deletion in the Gene Encoding the CD45 Antigen in a Patient with SCID

Elma Z. Tchilian,† Diana L. Wallace,* R. Spencer Wells, ‡ Darren R. Flower,* Gareth Morgan,* and Peter C. L. Beverley*

SCID is a heterogeneous group of hereditary diseases. Mutations in the common γ-chain (γc) of cytokine receptors, including those for IL-2, IL-4, IL-7, IL-9, and IL-15, are responsible for an X-linked form of the disease, while mutations of several other genes, including Janus-associated kinase-3, may cause autoimmune recessive forms of SCID. We investigated the first SCID patient to be described with minimal cell surface expression of the leukocyte common (CD45) Ag. CD45 is an abundant transmembrane tyrosine phosphatase, expressed on all leukocytes, and is required for efficient lymphocyte signaling. CD45-deficient mice are severely immunodeficient and have very few peripheral T lymphocytes. We report here that a homozygous 6-bp deletion in the gene encoding CD45 (PTPRC, gene map locus 1q31–32), which results in a loss of glutamic acid 339 and tyrosine 340 in the first fibronectin type III module of the extracellular domain of CD45, is associated with failure of surface expression of CD45 and SCID. Molecular modeling suggests that tyrosine 340 is crucial for the structural integrity of CD45 protein. This is the second description of a clinically relevant CD45 mutation, provides direct evidence for the importance of CD45 in immune function in humans, and suggests that abnormalities in CD45 expression are a possible cause of SCID in humans. The Journal of Immunology, 2001, 166: 1308–1313.

Cale et al. (26) described an SCID patient from consanguineous parents with minimal cell surface expression of CD45. Recently, a second SCID patient lacking surface CD45 expression has been investigated, and the genetic lesions in the CD45 gene identified (27). Here we show that the patient described by Cale et al. (26) has a homozygous 6-bp deletion in the CD45 gene, which results in a loss of glutamic acid 339 and tyrosine 340 in the first fibronectin type III module of the extracellular domain of CD45 and is responsible for the lack of cell surface expression of CD45. These findings confirm that CD45 is essential for lymphocyte development and signaling and that abnormalities in CD45 expression can be a cause of SCID in humans.

Materials and Methods

Patient material

Fresh blood and frozen PBMC were obtained from the G. family from the Department of Immunology and Infectious Diseases, Great Ormond Street Hospital National Health Service Trust (London, U.K.) (26). EBV-transformed lymphoblastoid lines were derived from the parents, fresh material from the SCID patient was very limited, and it proved impossible to derive an EBV line. Genomic DNA samples from European populations were provided by W. F. Bodmer (Institute of Molecular Medicine, University of Oxford, Oxford, U.K.). African pygmy samples were provided by L. L. Cavalli-Sforza (Department of Genetics, Stanford University School of Medicine, Stanford, CA). Samples from the Caucasus, Iran, and Central Asia were obtained as part of the anthropological expedition EurAsia ‘98 (see http://popgen.well.ox.ac.uk/eurasia for more details).

Immunofluorescence

Liquid nitrogen-stored PBMC from members of family G, Chinese hamster ovary (CHO), and EL-4 CD45 transfectants were surface stained with the following mAbs against human isoforms CD45R0-PE, CD45RB-FITC, and CD45RA-PE (Dako, Carpinteria, CA) or with pan-CD45-PE (Phar-Mingen, San Diego, CA) or pan-CD45 hybridoma supernatant (2D1, Imperial Cancer Research Fund, London, U.K.) with second layer Fab(1)2 sheep anti-mouse Ig-FITC (Sigma, St. Louis, MO). Isotype-matched mAbs were used as controls. Ten thousand events were collected on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA) and analyzed using CellQuest software.

*The Edward Jenner Institute for Vaccine Research, Compton, United Kingdom; †Imperial Cancer Research Fund Cancer and Immunogenetics Laboratory, Wellcome Trust Center for Human Genetics, University of Oxford, Oxford, United Kingdom; and ‡Medical Research Council Laboratories, Fajara, The Gambia

Received for publication October 3, 2000. Accepted for publication October 11, 2000.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† Address correspondence and reprint requests to Dr. Elma Z. Tchilian, The Edward Jenner Institute for Vaccine Research, Compton, Berkshire, U.K. RG20 7NN. E-mail address: elma.tchilian@jenner.ac.uk

‡ Abbreviations used in this paper: CHO, Chinese hamster ovary; BMT, bone marrow transplantation.

Copyright © 2001 by The American Association of Immunologists 0022-1767/01/$02.00
Total RNA was extracted from frozen PBLs using Tri-Reagent (Sigma). First-strand cDNA synthesis on 4 μg of total RNA was performed using random hexadeoxynucleotide primers and the First-Strand cDNA Synthesis Kit (Pharmacia Biotech, Uppsala, Sweden). The CD45 cDNA was amplified using four pairs of primers, each pair amplifying ~1- to 1.3-kb results of the CD45 cDNA: pair 1, 5′-untranslated region forward (5′-CGCTCTGTTGAAGACACAC-3′) and ex10 reverse (5′-CATATTACCACTGGAATC-3′); pair 2, ex10 forward (5′-CTGGTTGAAGACACAC-3′) and ex17 reverse (5′-CAAGCTCTGGTGT CATC-3′); pair 3, ex16 forward (5′-GGCAGCTGATTACATCTG-3′) and ex28 reverse (5′-TCATCGAGGATCTGTCGCT-3′); and pair 4, ex27 forward (5′-GAAGGCAACACACACATGGA-3′) and 3′ untranslated region reverse (5′-GCTGCTGTAAGACACAC-3′). The PCR conditions for amplification of CD45 cDNA included 4-min incubation at 94°C followed by 30 reaction cycles (1 min at 94°C, 1 min at 55°C, 4 min at 72°C) and final 16-min extension at 72°C. The purified PCR products were subjected to direct automated sequencing using gene-specific primers.

PCR analysis for detection of the 1168–1173del

One hundred nanograms of genomic DNA was amplified by PCR using forward (5′-AATTAGAAAACCCCTGCAACC-3′) and reverse (5′-ACT TGGCCTTGAAGACACATGGA-3′) primers. The primers were in exon 11, on either side of the 1168–1173del and amplified fragments of 77 bp (mutant) or 83 bp (wild type). PCR conditions were as described above. The PCR products were analyzed on a 0.5% non-denaturing polyacrylamide gel or VisiGel Separation Matrix (Stratagene, La Jolla, CA), for amplification refractory mutation system-PCR analysis. The PCR products were used: forward primers, CD45FDEL (5′-CTGTAACCGCGCAATAGTG-3′) and reverse primer, CD45R (5′-AGGAATTTTACATATAAATGCAAG-3′); and reverse primer, CD45F (5′-CTGTAACCGCGCAATAGTG-3′) and forward primer, CD45FDEL (5′-CTGTAACCGCGCAATAGTG-3′). The PCR conditions for amplification of CD45 cDNA included 4-min incubation at 94°C followed by 30 reaction cycles (1 min at 94°C, 1 min at 55°C, 4 min at 72°C) and final 16-min extension at 72°C. The purified PCR products were subjected to direct automated sequencing using gene-specific primers.

Western blot analysis

CHO cell transfectants (4 × 10^6) were lysed in 500 μl of RIPA buffer for 30 min on ice. The supernatant was clarified by centrifugation at 10,000 × g for 10 min at 4°C. An equal amount of protein from each of the cell lysates was loaded and separated by 10% SDS-PAGE. The gel was transferred onto nitrocellulose membrane, and the membrane was blocked in PBS, 0.1% Tween 20, and 5% nonfat dry milk overnight at 4°C. CD45 protein was detected using mouse anti-human CD45 mAb (3 μg/ml; clone H131, Pharmingen) followed by anti-mouse IgG-HRP conjugate (1:25,000; Pierce & Warriner, Cheshire, U.K.), followed by reaction with SuperSignal WestPico Chemiluminescent Substrate (Pierce & Warriner) for 5 min.
high levels of CD45 Ag, providing direct evidence that the 1168–1173del is responsible for abnormal CD45 expression in leukocytes of the SCID patient. The same results were obtained when the EL-4 mouse thymoma cell line was transfected with these constructs (data not shown).

The mechanism underlying the lack of CD45 cell surface expression is unknown. The 1168–1173 bp deletion was identified by RT-PCR from the patient’s cells, suggesting that mRNA is produced. To see whether the 6-bp deletion affected CD45 expression at the protein level we performed Western blot analysis. The Western blot analysis detected CD45 protein with a $M_r$ of 220 kDa in mutant CD45 CHO cell transfectants, although at a reduced level compared with the wild-type CHO transfectant (Fig. 3b). These results suggest that the 1168–1173del may affect the proper folding, stability, and correct cellular localization of the mutant CD45 protein.

**Tyrosine 340 is crucial for the structural integrity of CD45**

The deleted glutamic acid 339 and tyrosine 340 are part of the first of three fibronectin type III modules believed to form part of the extracellular domain of CD45 (30, 31). Tyrosine 340 is conserved in all CD45 sequences (human, rat, mouse, chicken, shark, and puffer fish), and the equivalent tyrosine is also highly conserved in known fibronectin sequences (Fig. 4a). Although the crystal structure of the extracellular domain of CD45 has yet to be solved, a molecular model of the first fibronectin module could be constructed using COMPOSER (32) based on known fibronectin structures (Fig. 4b). The model suggests that this tyrosine makes important contributions to maintenance of the packed core of the fibronectin structure (33). Deletion of this residue is likely to seriously destabilize the fibronectin module, leading to unfolding and intracellular degradation.

**1168–1173del is not a common genetic polymorphism**

To rule out the possibility that the 1168–1173del mutation in the SCID patient represented a common genetic polymorphism, we analyzed its frequency in the general population. Using amplification refractory mutation system-PCR analysis (28) the 1168–1173del was not detected in 518 unrelated healthy controls from varied ethnic backgrounds, including Europe, Africa, and East and Central Asia. This analysis included samples from 39 Kurds as well as 176 individuals from related ethnic groups (Iranians, Armenians, Azeris, and Turkmen); all were negative for 1168–1173del. Therefore, the deletion does not appear to be a common genetic polymorphism and has only been detected in the patient and members of her family.

**Discussion**

CD45 Ag has long been postulated to be crucial for immune function. Mice lacking the CD45 gene are severely immunodeficient and have a very similar phenotype to the SCID patient described in this study, with low T cell and normal B cell numbers. Here we have provided evidence for the existence of at least one naturally occurring mutant form of human CD45 that is associated with SCID. We have identified a 6-bp deletion in the gene encoding CD45 that results in the loss of glutamic acid 339 and tyrosine 340 in the first fibronectin type III module of the extracellular domain of CD45, identifying a region of the molecule important for CD45 structural integrity and lack of surface CD45 expression, which is almost certainly responsible for the immune deficiency in this patient.

In addition, our study provides direct evidence, through the transfection of murine and hamster cells with wild-type and mutant alleles, that the 6-bp deletion is responsible for the failure of CD45 surface expression on the patient’s cells. The exact mechanism responsible for the lack of CD45 cell surface expression is unknown. RT-PCR analysis of CD45 cDNA in the patient’s family revealed comparable amounts of wild-type and mutant CD45 transcripts in the patient, her parents, and the healthy sibling, suggesting that the 1168–1173del may not affect CD45 expression at the transcriptional level. Furthermore Western blot analysis of the cell transfectants showed that CD45 protein is produced, although not expressed, at the cell surface. While it is difficult to extrapolate to the patient from cell culture studies, this suggests that the 1168–
1173del may affect the proper folding, stability, and correct cellular localization of the mutant CD45 protein. This is in accord with the molecular modeling, which shows that tyrosine 340 has a crucial role in maintaining structural integrity of the first fibronectin type III of the extracellular domain of CD45. Tyrosine 340 is a highly conserved topohydrophobic residue (33) responsible for key nonpolar interactions in the packed, hydrophobic core of the fibronectin module. Deletion of this residue would result in dramatic alterations in the thermodynamic stability of this module. This may lead to an inability of the fibronectin module to fold into a stable tertiary conformation, leading, through the exposure of otherwise buried, proteolytic cleavage sites in the unfolded protein, to a concomitant degradation by intracellular proteases (34). Further studies will be required to determine the precise mechanism for the lack of surface CD45 expression in the patient. For example, pulse-chase experiments could be used to follow the intracellular fate of the mutant molecules.

We have also examined the frequency of the mutant allele in 518 DNA samples, including 215 from ethnic groups related to the Kurdish patient. No examples of the 6-bp deletion were detected, suggesting that 1168–1173del is not a common genetic polymorphism. Very recently, another SCID patient lacking CD45 expression has been reported (27). This patient, similar to the case described here, was also presented at 2 mo of age and had greatly reduced numbers of peripheral T cells. The latter were unresponsive to mitogen, and despite normal B cell numbers, serum Ig levels decreased with age. Two separate genetic abnormalities, a large deletion on one allele and a point mutation at the other, distinct from that reported here, were shown to be associated with...
lack of CD45 expression on the patient’s cells. The fact that now two SCID patients with different genetic lesions in CD45 have been identified suggests that although disease-associated CD45 polymorphisms may be rare, they should be considered in SCID patients without any other known cause.

In addition to the association of SCID with the lack of CD45 surface expression, abnormalities of CD45 splicing have been recognized in humans. We and others have demonstrated that a point mutation in the fourth (A) exon of CD45 prevents normal splicing of the N-terminal region of the gene, so that activated lymphocytes of these individuals express both high and low m.w. CD45 isoforms, in contrast to the normal pattern of low m.w. isoform expression (22). While these individuals are apparently normal, no homozygotes have yet been identified. In contrast, families with a similar defect in CD45 splicing associated with hemophagocytic lymphohistiocytosis or erythrocytic hemophagocytosis have been described (23, 24). Recently, linkage of abnormal CD45 splicing with a 32-bp deletion in CCR5 (CCR5del32), which confers resistance to infection with HIV isolates that use CCR5 as a coreceptor, has been reported (25). Although in all these cases no abnormality in the CD45 gene has yet been identified, this is made difficult by the large size of CD45, which has been estimated to be >120 kb (35).

This study provides evidence for the crucial role of CD45 in immune functions in humans, identifies abnormalities in CD45 expression as a possible cause for SCID, and suggests that CD45 screening should be included in the investigation of SCID patients and other patients with unexplained immunodeficiency.

Acknowledgments
We thank the patient’s family and Drs. G. Davies, Fay Katz, and A. Barnicoat for help with patient samples; Drs. G. Blanco and M. Timon for helpful discussions; E. Diaz and Dr. M. Timon for help with DNA sequencing; and R. Thakrar for expert technical assistance.

References


